Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $15.20.
ONCT has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Oncternal Therapeutics in a research note on Friday, April 16th. Oppenheimer initiated coverage on shares of Oncternal Therapeutics in a research note on Tuesday, April 6th. They set an “outperform” rating and a $14.00 price objective on the stock. Brookline Capital Acquisition assumed coverage on shares of Oncternal Therapeutics in a research note on Tuesday, March 30th. They set a “buy” rating and a $16.00 price objective on the stock. Brookline Capital Management restated a “buy” rating and issued a $16.00 price target on shares of Oncternal Therapeutics in a research note on Tuesday, March 30th. Finally, Zacks Investment Research upgraded shares of Oncternal Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday.
A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its position in Oncternal Therapeutics by 24.7% during the 1st quarter. Millennium Management LLC now owns 395,304 shares of the company’s stock worth $3,289,000 after buying an additional 78,174 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Oncternal Therapeutics during the 1st quarter worth approximately $323,000. Jane Street Group LLC acquired a new stake in Oncternal Therapeutics during the 1st quarter worth approximately $191,000. Schonfeld Strategic Advisors LLC boosted its position in Oncternal Therapeutics by 42.9% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 101,200 shares of the company’s stock worth $842,000 after buying an additional 30,400 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in Oncternal Therapeutics during the 1st quarter worth approximately $3,621,000. Institutional investors and hedge funds own 20.03% of the company’s stock.
Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earnings data on Thursday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $1.11 million. Oncternal Therapeutics had a negative return on equity of 29.91% and a negative net margin of 520.20%. Analysts anticipate that Oncternal Therapeutics will post -0.59 EPS for the current year.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia.
See Also: Call Option Volume
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.